| Name | vitamin K epoxide reductase complex (protein family or complex) |
|---|---|
| Synonyms | Vitamin K epoxide reductase; Vitamin K epoxide reductase complex; Vitamin K epoxide reductases |
| Name | warfarin |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 20354686 | Molden E, Okkenhaug C, Ekker Solberg E: Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response. Eur J Clin Pharmacol. 2010 Mar 31. BACKGROUND: Several studies have linked mutations in the genes encoding cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex 1 (VKORC1) to a reduced warfarin dose requirement and an increased risk of bleeding with warfarin treatment, but the implementation of genotyping as routine practice is still controversial. |
81(1,1,1,1) | Details |
| 19479657 | Cavallari LH, Limdi NA: Warfarin pharmacogenomics. Curr Opin Mol Ther. 2009 Jun;11(3):243-51. The cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genes have recently been determined to be associated with warfarin dose requirements, with reduced doses of this drug being required in patients with the variant CYP2C9*2, CYP2C9*3, or VKORC1 -1639A allele. |
31(0,1,1,1) | Details |
| 19099951 | Yang J, Miao LY, Huang CR, Shen ZY, Jiang WP: [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements]. Zhonghua Xin Xue Guan Bing Za Zhi. 2008 Feb;36(2):137-40. OBJECTIVE: To assess the contribution of vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) genotype, age, body size, height, and weight to warfarin dose requirement. |
6(0,0,1,1) | Details |
| 19571807 | You JH, Tsui KK, Wong RS, Cheng G: Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin Pharmacol Ther. 2009 Nov;86(5):540-7. Epub 2009 Jul 1. We used decision-tree modeling to simulate the outcomes of CYP2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genotype-guided dosing in patients in whom warfarin therapy is to be initiated. |
6(0,0,1,1) | Details |
| 20140106 | Li J, Wang S, Barone J, Malone B: Warfarin pharmacogenomics. P T. 2009 Aug;34(8):422-7. Achieving safe and effective doses of warfarin therapy is both an urgent and important concern for many clinicians.Recent research has focused on single-nucleotide polymorphisms (SNPs) of genes that encode two proteins: the cytochrome P450 2C9 enzyme and VKORC1 (vitamin K epoxide reductase complex). |
6(0,0,1,1) | Details |
| 18752379 | Limdi NA, Veenstra DL: Warfarin pharmacogenetics. Pharmacotherapy. 2008 Sep;28(9):1084-97. We review the evidence of the influence of the two key genes of interest, the cytochrome P450 2C9 gene, CYP2C9, and the vitamin K epoxide reductase complex 1 gene, VKORC1, on warfarin response and discuss the implications of current knowledge for clinical practice. |
6(0,0,1,1) | Details |
| 18535201 | Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008 Aug 15;112(4):1022-7. Epub 2008 Jun 5. Warfarin dosing is correlated with polymorphisms in vitamin K epoxide reductase complex 1 (VKORC1) and the cytochrome P450 2C9 (CYP2C9) genes. |
6(0,0,1,1) | Details |
| 18763667 | LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip R, Duconge J, Ruano G: Integrating genomic based information into clinical warfarin management: an illustrative case report. Conn Med. 2008 Aug;72(7):399-403. A second enzyme, Vitamin K Epoxide Reductase Complex (VKORC) binds and reduces which is necessary for activation of clotting Factors II, VII, IX and X. |
1(0,0,0,1) | Details |
| 18240910 | Wu AH: Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics. 2007 Jul;8(7):851-61. Recently, polymorphisms in two genes, cytochrome P450 2C9 and vitamin K epoxide reductase complex 1, have been shown to affect warfarin's pharmacogenomics and pharmacodynamics, respectively. |
1(0,0,0,1) | Details |